Novel agents for the treatment of adenocarcinoma of the pancreas (Q37614590)

21 August 2017

1 reference

title

Novel agents for the treatment of adenocarcinoma of the pancreas (English)

1 reference

21 August 2017

0 references

1 reference

R Pamela Mackenzie

1

1 reference

PubMed ID

19828009

21 August 2017

A David McCollum

series ordinal

2

1 reference

21 August 2017

1 October 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

1473-1485

1 reference

21 August 2017

10

1 reference

Global cancer statistics, 2002

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Albumin-bound paclitaxel: a next-generation taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Pancreatic cancer: from molecular pathogenesis to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Targeted therapies for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Pancreatic cancer: from molecular signature to target therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Genetics and biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Apoptotic pathways in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Incidence, mechanism and prognostic value of activated AKT in pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Mechanisms of proteasome inhibitor action and resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.109

21 January 2018

Identifiers

DOI

10.1586/ERA.09.109

1 reference

21 August 2017

1 reference

PubMed ID

19828009